 |
Video: What is a Stock Split?
|
 |
Alpine Immune Sciences is a clinical-stage biopharmaceutical company focused on discovering and developing protein-based immunotherapies to autoimmune and inflammatory diseases. Co.'s ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor, and a proliferation inducing ligand, cytokines, which play the roles in the activation, development, and survival of B cells. Co.'s ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator and CD28 antagonist used for the treatment of autoimmune and inflammatory diseases. In immuno-oncology, Co.'s ALPN-202 (davoceticept) is a conditional CD28 costimulator and dual checkpoint inhibitor used for the treatment of cancer. According to our ALPN split history records, Alpine Immune Sciences has had 1 split. | |
 |

Alpine Immune Sciences (ALPN) has 1 split in our ALPN split history database. The split for ALPN took place on July 25, 2017. This was a 1 for 4 reverse split, meaning for each 4 shares of ALPN owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 250 share position following the split.
When a company such as Alpine Immune Sciences conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the ALPN split history from start to finish, an original position size of 1000 shares would have turned into 250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Alpine Immune Sciences shares, starting with a $10,000 purchase of ALPN, presented on a split-history-adjusted basis factoring in the complete ALPN split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/18/2015 |
|
End date: |
03/28/2023 |
|
Start price/share: |
$59.00 |
|
End price/share: |
$7.22 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-87.76% |
|
Average Annual Total Return: |
-23.66% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,223.81 |
|
Years: |
7.78 |
|
|
 |
Date |
Ratio |
07/25/2017 | 1 for 4 |
|
 |